NCT03695510View on ClinicalTrials.gov

Afatinib and Pembrolizumab for Head and Neck Squamous Cell Carcinoma (ALPHA Study)

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

January 24, 2019

Primary Completion Date

April 14, 2022

Study Completion Date

April 14, 2022

Conditions
Head and Neck Neoplasms
Interventions
DRUG

Afatinib Oral Tablet

40mg oral, daily, continuously

DRUG

Pembrolizumab Injection

200mg, intra-venous injection, every 3 weeks, for 35 cycles

Trial Locations (1)

100

National Taiwan University Hospital, Taipei

All Listed Sponsors
lead

National Taiwan University Hospital

OTHER

NCT03695510 - Afatinib and Pembrolizumab for Head and Neck Squamous Cell Carcinoma (ALPHA Study) | Biotech Hunter | Biotech Hunter